

# Ataxia Telangiectasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/AEEEEA92481F5EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: AEEEEA92481F5EN

## Abstracts

The 7 major ataxia telangiectasia markets reached a value of US\$ 585.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1,270.2 Million by 2034, exhibiting a growth rate (CAGR) of 7.3% during 2024-2034.

The ataxia telangiectasia market has been comprehensively analyzed in IMARC's new report titled "Ataxia Telangiectasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ataxia telangiectasia (A-T) refers to a rare genetic disorder that primarily affects the nervous and immune systems. The hallmark feature of the condition is progressive ataxia (uncoordinated movement), leading to difficulties with balance, walking, and fine motor skills. Additionally, telangiectasias (small, dilated blood vessels) commonly appear on the skin and mucous membranes, particularly in the eyes and ears. Individuals suffering from A-T may experience progressive neurologic decline, including slurred speech, tremors, difficulty swallowing, etc. Besides this, immune system impairment can lead to recurrent respiratory infections and increased susceptibility to illnesses. Patients may also exhibit a heightened sensitivity to ionizing radiation and an elevated risk of developing lymphoma and leukemia. The diagnosis of ataxia telangiectasia typically involves a combination of clinical evaluation, genetic testing, and imaging procedures. Several imaging studies, such as magnetic resonance imaging (MRI) of the brain, may reveal cerebellar abnormalities. Additionally, immune function tests and alpha-fetoprotein (AFP) screening help in assessing immune deficiencies and monitoring for potential cancer development. However, genetic testing is essential to confirm the presence of mutations in the ataxia telangiectasia mutated (ATM) gene, which aids in establishing a definitive diagnosis.

The increasing cases of inherited genetic mutations in the ATM gene, leading to impaired DNA repair mechanisms and genomic instability, are primarily driving the ataxia telangiectasia market. Moreover, the inflating application of certain neurological medications, such as anticonvulsants, to control seizure activity and improve the patient's overall neurological well-being is also creating a positive outlook for the market. Apart from this, the widespread adoption of DNA repair enhancers, including poly ADP-ribose polymerase (PARP) inhibitors, for counteracting the defective DNA repair mechanisms observed in A-T is acting as another significant growth-inducing factor. Furthermore, various key players are making extensive investments in R&D activities to introduce small molecule drugs that can activate the residual ATM protein in A-T patients in order to enhance cellular function. This, in turn, is also propelling the market growth. Additionally, the emerging popularity of whole-exome sequencing (WES), since it aids in identifying new and rare genetic mutations associated with the ailment, thereby leading to a better understanding and diagnosis, is expected to drive the ataxia telangiectasia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the ataxia telangiectasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for ataxia telangiectasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ataxia telangiectasia market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the ataxia telangiectasia market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the ataxia telangiectasia market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current ataxia telangiectasia marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report: Market Insights

How has the ataxia telangiectasia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the ataxia telangiectasia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the ataxia telangiectasia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of ataxia telangiectasia across the seven major markets?

What is the number of prevalent cases (2018-2034) of ataxia telangiectasia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of ataxia telangiectasia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with ataxia telangiectasia across the seven major markets?

What is the size of the ataxia telangiectasia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of ataxia telangiectasia?

What will be the growth rate of patients across the seven major markets?

## Ataxia Telangiectasia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for ataxia telangiectasia drugs across the

seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ataxia telangiectasia market?

What are the key regulatory events related to the ataxia telangiectasia market?

What is the structure of clinical trial landscape by status related to the ataxia telangiectasia market?

What is the structure of clinical trial landscape by phase related to the ataxia telangiectasia market?

What is the structure of clinical trial landscape by route of administration related to the ataxia telangiectasia market?

## Contents

?1 Preface

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 ATAXIA TELANGIECTASIA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 ATAXIA TELANGIECTASIA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 ATAXIA TELANGIECTASIA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 ATAXIA TELANGIECTASIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 ATAXIA TELANGIECTASIA - UNMET NEEDS**

## **10 ATAXIA TELANGIECTASIA - KEY ENDPOINTS OF TREATMENT**

## **11 ATAXIA TELANGIECTASIA - MARKETED PRODUCTS**

- 11.1 List of Ataxia Telangiectasia Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 ATAXIA TELANGIECTASIA - PIPELINE DRUGS**

### 12.1 List of Ataxia Telangiectasia Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 IB1001 - IntraBio

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 GTX 102 - Acasti Pharma

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. ATAXIA TELANGIECTASIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. ATAXIA TELANGIECTASIA – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 ATAXIA TELANGIECTASIA - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Ataxia Telangiectasia - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Ataxia Telangiectasia - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

- 15.3.1 Ataxia Telangiectasia - Market Size
  - 15.3.1.1 Market Size (2018-2023)
  - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Ataxia Telangiectasia - Market Size by Therapies
  - 15.3.2.1 Market Size by Therapies (2018-2023)
  - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Ataxia Telangiectasia - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Ataxia Telangiectasia - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Ataxia Telangiectasia - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Ataxia Telangiectasia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Ataxia Telangiectasia - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Ataxia Telangiectasia - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Ataxia Telangiectasia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Ataxia Telangiectasia - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Ataxia Telangiectasia - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Ataxia Telangiectasia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Ataxia Telangiectasia - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Ataxia Telangiectasia - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Ataxia Telangiectasia - Access and Reimbursement Overview

## 15.8 Market Scenario - Spain

### 15.8.1 Ataxia Telangiectasia - Market Size

#### 15.8.1.1 Market Size (2018-2023)

#### 15.8.1.2 Market Forecast (2024-2034)

### 15.8.2 Ataxia Telangiectasia - Market Size by Therapies

#### 15.8.2.1 Market Size by Therapies (2018-2023)

#### 15.8.2.2 Market Forecast by Therapies (2024-2034)

### 15.8.3 Ataxia Telangiectasia - Access and Reimbursement Overview

## 15.9 Market Scenario - Japan

### 15.9.1 Ataxia Telangiectasia - Market Size

#### 15.9.1.1 Market Size (2018-2023)

#### 15.9.1.2 Market Forecast (2024-2034)

### 15.9.2 Ataxia Telangiectasia - Market Size by Therapies

#### 15.9.2.1 Market Size by Therapies (2018-2023)

#### 15.9.2.2 Market Forecast by Therapies (2024-2034)

### 15.9.3 Ataxia Telangiectasia - Access and Reimbursement Overview

## **16 ATAXIA TELANGIECTASIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 ATAXIA TELANGIECTASIA MARKET - SWOT ANALYSIS**

### 17.1 Strengths

### 17.2 Weaknesses

### 17.3 Opportunities

### 17.4 Threats

## **18 ATAXIA TELANGIECTASIA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Ataxia Telangiectasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/AEEEEA92481F5EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AEEEEA92481F5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

